Navigation Links
The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent
Date:3/13/2008

ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year. These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007. Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.

"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."

At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the overall MACE rate in the ABSORB trial was consistent with results at 6 months (one patient, 3.3 percent, n=30; 3.4 percent adjusted for one patient who withdrew from follow-up, known to be event free at 1 year, n=29). MACE is a composite measure of cardiac death, hear
'/>"/>

Contact: Karin Bauer
408-845-3887
Abbott Laboratories
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Two studies published in the Lancet
2. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
3. MediPurpose Sells 500 Millionth Safety Lancet to IMCO Member MMS Medical
4. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
5. American College of Physicians publishes The Fenway Guide to LGBT Health
6. In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish
7. Multiple Sclerosis Association of America Publishes Booklet about Depression in Multiple Sclerosis
8. American College of Physicians publishes "Peripheral Arterial Disease"
9. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 Barbara Crone ... worked to enhance the well being of the men, women and ... a hospital, followed by providing care for families in the home. ... an Adult Nurse Practitioner began wondering if I could complete their ... of my own children with my mentor Nurse Midwife, I knew ...
(Date:5/3/2015)... Bubbly Walrus ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... to play on smartphones are the ones that get users ... a video game that just absorbs attention, why not exercise ...
(Date:5/3/2015)... May 03, 2015 NuevaCare announced today ... two upcoming area seminars. The first event will take ... Regional Stroke Conference to be held at The Magnolia ... Wednesday, May 13 during the Dementia Conference to be ... “These seminars offer an excellent opportunity to learn about ...
(Date:5/2/2015)... 2015 As one of only 30 ... Safety and Health Achievement and Recognition Program (SHARP) certification, ... chosen by the Illinois Department of Labor to host ... maintained SHARP certification by the Occupational Safety and Health ... has continued to meet or exceed all of the ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3
... Inc. told the National Heritage Insurance Co., the contractor that ... to cover its test. ,After this the company’s ... to $12.41 on Nasdaq. The company prepares oncotype DX breast ... taking all the responsibility to cover the medical expenses related ...
... virus has been steadily increasing, with more// than 50 ... in other parts of the territory. // Furthermore, reports of ... past three weeks has prompted reasons for concern among the ... occurred has been one that hit Darwin a decade ago ...
... time from six weeks to five days. This is very useful ... can point the radiation source at the tumor killing the cancer ... therapy over the conventional six-week treatment. They are also in the ... ,But the Canadians are working on a new therapy for breast ...
... Scientist working at the DeCode Genetics Inc (Reykjavik company) was ... the diabetic population in US. ,The Icelandic ... is not known, but is thought to regulate the genes ... in the Icelandic population, as they are a close nit ...
... Pathology, University of Michigan Medical School has reported in ... for producing hypersensitive immune response leading to autoimmune disease. ... the bacteria against which the protein produces an immune ... the immune system to produce an immune response against ...
... the fourth largest reservoir of scientific and research talent ... is poised to emerge as the preferred hub for ... knowledge economy are not restricted to information and communication ... biotech, nanotechnology, missile technology and space. ,India's ...
Cached Medicine News:Health News:Western Australia Witnesses Rise In Ross River Virus Infection 2Health News:Gene Linked To Type 2 Diabetes Identified 2Health News:India set to become the global knowledge hub 2Health News:India set to become the global knowledge hub 3Health News:India set to become the global knowledge hub 4
(Date:5/1/2015)... May 1, 2015  CytRx Corporation (CYTR), a ... today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its ... milestones in the early months of 2015, including ... trial of aldoxorubicin in patients with soft tissue ...
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) today ... 2015, as well as general business updates. Due to ... be held. Key Highlights , Total ... to $206 million from $119 million for the quarter ... (ibrutinib) net product revenue of $247 million was ...
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Timothy E. Morris , chief financial officer  will ... the events are as follows: Mizuho Third ... Location:  The Omni Berkshire Place, New York ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26
... Greenway Medical Technologies, Inc. and the Physician ... (INHS) today announced an agreement for INHS to ... practice management solution PrimeSUITE® 2011 to ... coordination and network interoperability. Established more ...
... Cohera Medical, Inc.®, a rapidly growing medical device company, ... for its lead product, TissuGlu® Surgical Adhesive. ... sold in the European Union. TissuGlu ... surgeries, such as abdominoplasties, that helps reduce fluid accumulation ...
Cached Medicine Technology:Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
Insert only, Ethicon medium-large clip size...
Ethicon, medium-large clip size, 10mm, rotatable take apart...
... and IMMULITE 1000 assays are ... IMMULITE and IMMULITE 1000, continuous ... offer simplicity in both design ... be found in a wide ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: